Taiwan Liposome Company, Ltd.

Tlc Biopharmaceuticals, Inc.

Tcl Biopharmaceuticals, Inc.

Sheue-Fang Shih

Yun-Long Tseng

Po-Chun Chang

Keelung Hong

Luke S S Guo

Chih-Chiang Tsai

Hong-Hui Lin

Hong-Hul Lin

Yi-yu Lin

Hao-wen Kao

Wan-Ni Yu

Min-Wen Kuo

Ming-Ju Wu

Pei-hsien Hu

Hsiu-Li Song

Lo Chang

Carl Oscar Brown

Tien-Tzu Tai

Hui-ting Wang

Weenee Yeun Ng Jao

Luke Ss Guo

Luke SS Guo

Hsin-Yi Chiu

Provided is a pharmaceutical composition for use in treating postsurgical pain. The pharmaceutical composition comprises a lipid-based complex. The lipid-based complex comprises an amide-type anesthetic and at least one lipid, wherein a molar ratio of the amide-type anesthetic to the at least one lipid of the lipid-based complex is at least 0.5:1. The total amount of the amide-type anesthetic is at least 1.5 to 5 times of a standard therapeutic dose for treating postsurgical pain with the amide-type anesthetic to achieve an improved pain control with desired prolonged analgesic effect.

Pharmaceutical compositions for use in treating pain

The present disclosure relates to pharmaceutical composition for the treatment of joint pain. The composition contains a lipid mixture comprising one or more phospholipids; and an effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, where the total amount of phospholipids in said composition is about 20 mM to about 150 mM, optionally 70 mM to 110 mM. Also provided is the use of the pharmaceutical composition in the treatment of joint pain by articular injection.

Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Provided are methods of treating joint pain, comprising administering to a subject in need of joint pain treatment an effective amount of a pharmaceutical composition comprising a lipid mixture comprising one or more lipids; and an effective amount of an intra-articular steroid or a pharmaceutically acceptable salt thereof, wherein the therapeutic efficacy of the intra-articular steroid is sustained but the side effects associated with the intra-articular steroid are reduced.

Methods to reduce complications of intra-articular steroid

The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Pharmaceutical composition for intraarticular delivery

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

Drug delivery system containing phospholipid and cholesterol

Pharmaceutical compositions for intraarticular delivery

Methods of treating arthritis

Ophthalmic drug delivery system containing phospholipid and cholesterol

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Pharmaceutical compositions to reduce complications of ocular steroid

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.

Anti-VEGF monoclonal antibody

Growing community of inventors

Taipei, Taiwan

Sheue-Fang Shih